Ascentage Pharma's Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients

Reuters

07/10

<a href="https://laohu8.com/S/AAPG">Ascentage Pharma</a>'s Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients

Ascentage Pharma Group International has announced that its novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), has received approval from China's National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously undergone at least one systemic therapy, including Bruton's tyrosine kinase $(BTK.AU)$ inhibitors. This marks lisaftoclax as the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for CLL/SLL treatment in China, and the second such inhibitor approved globally. Developed by Ascentage Pharma, lisaftoclax aims to restore the normal apoptosis process in cancer cells by selectively blocking the antiapoptotic protein Bcl-2. The approval is based on positive results from a pivotal registrational Phase II study, highlighting Ascentage Pharma's capabilities in global clinical development and innovation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on July 10, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2550612672"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550612672\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550612672?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-10 16:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550612672","market":"fut","top_or_hot":-1,"title":"Ascentage Pharma's Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AAPG\">Ascentage Pharma</a>'s Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ASPHF\">Ascentage Pharma</a> Group International has announced that its novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), has received approval from China's National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously undergone at least one systemic therapy, including Bruton's tyrosine kinase <a href=\"https://laohu8.com/S/BTK.AU\">$(BTK.AU)$</a> inhibitors. This marks lisaftoclax as the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for CLL/SLL treatment in China, and the second such inhibitor approved globally. Developed by Ascentage Pharma, lisaftoclax aims to restore the normal apoptosis process in cancer cells by selectively blocking the antiapoptotic protein Bcl-2. The approval is based on positive results from a pivotal registrational Phase II study, highlighting Ascentage Pharma's capabilities in global clinical development and innovation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on July 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascentage Pharma's Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscentage Pharma's Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-10 16:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AAPG\">Ascentage Pharma</a>'s Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ASPHF\">Ascentage Pharma</a> Group International has announced that its novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), has received approval from China's National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously undergone at least one systemic therapy, including Bruton's tyrosine kinase <a href=\"https://laohu8.com/S/BTK.AU\">$(BTK.AU)$</a> inhibitors. This marks lisaftoclax as the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for CLL/SLL treatment in China, and the second such inhibitor approved globally. Developed by Ascentage Pharma, lisaftoclax aims to restore the normal apoptosis process in cancer cells by selectively blocking the antiapoptotic protein Bcl-2. The approval is based on positive results from a pivotal registrational Phase II study, highlighting Ascentage Pharma's capabilities in global clinical development and innovation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on July 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06855","symbol_name":"亚盛医药-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nNDLb2Pvrx:1","article_id":"2550612672","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550612672","pubTimestamp":1752137866,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ascentage Pharma Group International has announced that its novel Bcl-2 selective inhibitor, lisaftoclax , has received approval from China's National Medical Products Administration  for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma  who have previously undergone at least one systemic therapy, including Bruton's tyrosine kinase  inhibitors. This marks lisaftoclax as the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for CLL/SLL treatment in China, and the second such inhibitor approved globally. Developed by Ascentage Pharma, lisaftoclax aims to restore the normal apoptosis process in cancer cells by selectively blocking the antiapoptotic protein Bcl-2. The approval is based on positive results from a pivotal registrational Phase II study, highlighting Ascentage Pharma's capabilities in global clinical development and innovation.Disclaimer: This news brief was created by Public Technologies  using genera","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06855":"亚盛医药-B","BK1574":"生物医药B类股","BK1161":"生物科技"},"translate_title":"亚盛医药新型Bcl-2抑制剂Lisaftoclax获中国NMPA批准用于治疗CLL/SLL患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":0.9},"content_text":"Ascentage Pharma's Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients\n    \n\nAscentage Pharma Group International has announced that its novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), has received approval from China's National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously undergone at least one systemic therapy, including Bruton's tyrosine kinase $(BTK.AU)$ inhibitors. This marks lisaftoclax as the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for CLL/SLL treatment in China, and the second such inhibitor approved globally. Developed by Ascentage Pharma, lisaftoclax aims to restore the normal apoptosis process in cancer cells by selectively blocking the antiapoptotic protein Bcl-2. The approval is based on positive results from a pivotal registrational Phase II study, highlighting Ascentage Pharma's capabilities in global clinical development and innovation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on July 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}